The formerly fully integrated pharma value chain is disaggregating given the emergence of highly capable and specialized research and clinical development service providers. The options range from outsourcing, out-licensing, and in-licensing, strategic partnerships and co-development. These concepts are discussed in detail and illustrated with cases from industry. We conclude with an example of how a breakthrough innovation can best be commercialized by a small pharma company using those make-or-buy options.
CITATION STYLE
Gassmann, O., Schuhmacher, A., von Zedtwitz, M., & Reepmeyer, G. (2018). The Make-or-Buy Challenge: How to In- and Outsource Innovation. In Leading Pharmaceutical Innovation (pp. 79–110). Springer International Publishing. https://doi.org/10.1007/978-3-319-66833-8_5
Mendeley helps you to discover research relevant for your work.